Muhammad Akram

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

Jesús G. Berdeja, Deepu Madduri, Saad Z. Usmani et al. · The Lancet · 2021 · 1.5K citations

Hematological Malignancy, Cell Therapy, Immunotherapy +11

Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies

Adam D. Cohen, Samir Parekh, Bianca Santomasso et al. · Blood Cancer Journal · 2022 · 235 citations · Full text

Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents

Adam D. Cohen, María‐Victoria Mateos, Yaël C. Cohen et al. · Blood · 2022 · 182 citations · Full text

Hematological Malignancy, Adverse Events, Autoimmune Disease +15

Modulation of Mitochondrial Function and Autophagy Mediates Carnosine Neuroprotection Against Ischemic Brain Damage

Seung‐Hoon Baek, Ah Reum Noh, Kyeong-A. Kim et al. · Stroke · 2014 · 179 citations · Full text

Allelochemicals: sources, toxicity and microbial transformation in soil —a review

Ghulam Jilani, S. Mahmood, Arshad Nawaz Chaudhry et al. · Annals of Microbiology · 2008 · 130 citations · Full text